Flatiron Health’s Post

2024 is upon us, and ACRP has identified four trends shaping clinical trials this year: 1. Decentralized trials 2. Digitized patient experiences 3. Diversity and equity 4. Patient concierge services These trends highlight the need to put patient needs and experiences at the forefront of research. Learn more: https://lnkd.in/ga34VnRq What trends do you think are impacting research most currently, and what improvements can be made? Leave them in the comments! #clinicaltrials #cancerresearch #cancer #research #healthcare #health #clinicalresearch #MNCCTN

This piece of research set out to examine which interventions best promote safety, particularly in an oncology setting. It’s interesting to note that, of all the practices they investigated, the authors concluded that “implementation of incident learning systems seems to hold most promise.” Talk to us about After Action Review, as well as the new Eva Applications AAR app in development to help support your safety culture in healthcare and beyond. #AAR #AfterActionReview #patientsafety #PSIRF https://lnkd.in/e63_wQt4  

FCS Partners with Paradigm to Expand Clinical Trial Access - HIT Consultant #FCS_Partnership_with_Paradigm FCS, a leading healthcare IT company, has partnered with Paradigm to enhance access to clinical trials for patients. This collaboration aims to streamline the process of finding and enrolling in clinical trials, ultimately benefiting both patients and healthcare providers. #Benefits_of_the_Partnership The partnership between FCS and Paradigm will provide patients with a wider range of clinical trial options, allowing them to access cutting-edge treatments and therapies. Healthcare providers will benefit from improved efficiency in patient recruitment and enrollment, leading to faster trial completion and data collection. #Enhanced_Technology_Solutions FCS will leverage its advanced technology solutions to enhance the clinical trial experience for both patients and providers. ai.mediformatica.com #cancer #clinical #clinicaltrial #research #paradigm #platform #acce #clinicaltrials #collaboration #health #partners #partnership #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4gbDxv1)

Geography shouldn’t hold people back from being able to join a clinical trial that could save their life. But with many clinical trials concentrated in predominantly metropolitan areas, accessing a clinical trial is harder than it should be. Clinical trials offer patients access to new treatments, while also providing data to improve medical knowledge and help shape the development of new treatments. Increasing participation in clinical trials also plays a crucial role in improving outcomes. That’s why our Rare Cancer Moonshot recognises the need for equitable access to clinical trials. One of our recommendations is for government, healthcare providers and industry to work together to create novel trial design and expand telehealth services – making more clinical trials available to more patients. Read more in our Rare Cancer Moonshot report at: https://bit.ly/4dB8FCn

We sat down with Nate Wade, PharmD, MBA, BCOP, to talk about the role of electronic health records in precision medicine. Dr. Wade spoke as part of a session titled “Deep Dive: EHR Integration: A Key Component of Precision Medicine,” at the Association of Cancer Care Centers 50th Annual Meeting & Cancer Center Business Summit. "It's an exciting time to work in precision medicine and technology, because we're getting close to that vision of having a tool at each point in the timeline to help enable clinicians to provide better care ... We've kind of accomplished it in some ways, but there's still a lot of work that remains," said Dr. Wade. Watch the full video here 👉 https://lnkd.in/e9Ag2N5u #JournalOfClinicalPathways #PrecisionMedicine #EHR #ElectonicHealthRecord #HealthTechnology #ValueBasedCare

🔬 Every new cancer treatment breakthrough brings hope but also raises a crucial question: How do we balance these advances with the high costs that limit patient access? Developing these innovative therapies is incredibly costly. Treatments like CAR T-cell therapies and management of adverse events such as Cytokine Release Syndrome (CRS) can run into hundreds of thousands of dollars, creating barriers for many patients, especially those without financial resources. The high costs and complexities associated with CRS underscore the urgent need for innovative solutions to improve patient access and safety. 📲📈 Digital Health Technologies (DHTs) can unlock cost efficiency in clinical trials by: - Reducing clinical visits and shortening trial length - Enhancing recruitment, diversity, and participant completion - Increasing availability of evidentiary and safety requirements By integrating DHTs, we can potentially reduce overall treatment costs and improve patient outcomes, making a significant impact in managing high-risk therapies. 🌟 Advancing Outpatient Care with DHTs Shifting the administration of these therapies for select patients to outpatient settings is becoming a reality thanks to these technologies that allow remote monitoring for CRS. A current initiative hosted by the Digital Health Measurement Collaborative Community (DATAcc) by Digital Medicine Society (DiMe) is also pioneering efforts to advance the development of digital measures and risk prediction tools for CRS, which could revolutionize how we manage and treat this condition. (More to come here: https://lnkd.in/ebQ_zbGv) 💡 I’m thrilled to share my latest insights on this topic. Check it out at The Health Care Blog to explore how digital health innovations are paving the way for safer and more accessible treatments. https://lnkd.in/eAE4peKX Let’s continue to push for progress and improve patient care. 👏 #CancerTreatment #CRS #DigitalHealth #Telemedicine #ClinicalTrials #CAR-T #HealthcareInnovation #PatientSafety

What is theranostocs? Theranostics is an advanced, integrative approach to healthcare that combines #diagnostics and #therapeutics to enhance personalized and precise medical care. Theranostics has transformed the way we provide medical care and has revolutionized the way we think about personalized medicine, especially in cancer treatment. Theranostics, a combination of therapy and diagnostics, is an approach within #personalizedmedicine that uses radioactive drugs both to diagnose and treat specific cancer types. This method pairs diagnostic and therapeutic biomarkers with different radiotracers targeting the same tumor. Both the diagnostic and therapeutic radiotracers attach to the same specific biological markers. This integration allows for highly #targetedtreatments based on precise #diagnosticdata, improving treatment efficacy and reducing side effects, and ensuring that treatments are specific to the patient’s unique tumor profile. In the last 10 years, theranostics has emerged as an innovative, new approach to tailored disease management. But, what exactly is theranostics? How is it being used today? And what issues must be addressed to unlock its full potential in the years ahead? This paper by Siemens Healthineers evaluates the strategic importance of theranostics and discusses how it can be deployed in #healthcaresystems today. It also assesses its potential in terms of improving patient outcomes, operational efficiency, and #patientcare standards. In order to make effective use of theranostics, healthcare leaders can gain a competitive advantage by having a clear understanding of how to integrate it into their services. In the coming years, the growth of #theranostics is projected to be significant. The global theranostics market is currently valued at more than US$2 billion, and some projections anticipate a compound annual growth rate of more than 13% between now and 2032. Currently, many healthcare institutions and outpatient clinics are establishing theranostics programs to meet the demand of the increasing patient volume. Increasing the number of theranostics facilities can contribute to reducing long waiting lists and enable timely treatment for patients.  

BE PIONEERING: The benefits of unlocking the value of diagnostic innovation in Alzheimer’s [Promoted content]: There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to transform timely, accurate diagnosis for the benefit of patients and healthcare systems.

Early diagnosis, increased awareness and effective therapies have improved outcomes of patients with AL amyloidosis. Future should focus on unmet clinical needs, development of patient centric clinical trials with PROs as endpoints and by engaging and collaboration with all stakeholders. #amyloidosis #raredisease

Unlocking Efficiency in Your Oncology Practice with EMRs The ever-changing oncology care landscape demands efficient workflows to deliver exceptional patient outcomes. However traditional paper-based systems create roadblocks. EMR systems can be a game-changer! They streamline workflows, improve data management, and empower data-driven decision-making. But with so many EMR options, how do you choose the right one? Read our latest blog post to discover how nuQare EMR, a cutting-edge oncology-specific EMR system, can unlock efficiency in your practice - https://lnkd.in/dTt9hNFm #oncology #EMR #healthcare #efficiency #patientcare